Introduction to Shanghai Artemed Hospital
Shanghai Artemed Hospital was established jointly by Gaobo Healthcare Group, Silver Mountain Capital and Germany's Artemed Group. It is the first foreign-funded general hospital in Shanghai Free Trade Zone and also a pilot project for the further opening up of the service sector. The Hospital has a planned construction floor area of about 60,000 square meters, 200 beds opened in the first phase and about a total of 500 beds by the end of the second phase. Since its initiation, it has planned to provide high-quality medical services in line with international standards with more competitive prices and technological advantages targeting the mass and middle markets based on its own advantages and the needs of the Chinese market.
Shanghai Artemed Hospital is aimed at being an international research hospital that will bring together a team of top clinical experts and research talents at home and abroad to promote concurrent development in medical practice, education and research. The Hospital offers various specialties including oncology, orthopedics, emergency medicine, intensive care medicine, rehabilitation medicine, medical imaging, and medical laboratory science. It encourages the new medical models of integrated care and team-based care, focuses on clinical research and translational innovation, and regards “The Needs Of The Patient Come First” as its foundation.
Germany's Artemed Group is a world-renowned healthcare operation group providing advanced medical services and elder care services. It operates 14 hospitals and 6 senior facilities in Germany. Artemed Group is a leader in the German medical and elder-care market. Its hospitals have topped the German hospital rankings for a long time with excellent clinical results and the highest satisfaction of all health care facilities available for German patients (90% satisfaction). Moreover, these hospitals stand at the forefront of various health fields such as pathological diagnosis and surgery related to musculoskeletal diseases, artery and vein disorders, and coronary heart diseases, as well as in the transplantation of human organs in Europe. Meanwhile, the Artemed Group’s hospitals are at the leading edge of medical academic research in Germany, and the staff members have published many best-selling books on hospital management in Germany
Gaobo Healthcare Group is an oncology medical service organization wholly-owned by Hillhouse Capital. The Group is committed to building a medical service and technology innovation platform that focuses on the treatment of tumors by integrating medical practice, industry and research. Shanghai Artemed Hospital takes advantage of Gaobo Healthcare Group to focus on comprehensive medical services involving precise diagnosis of tumors, integrated treatment and full lifecycle management. With the international resources of Hillhouse Capital, Shanghai Artemed Hospital will also cooperate with many top international medical centers, such as Mayo Clinic, Massachusetts General Hospital (MGH) and UCSF Medical Center, to collaborate on medical technology transfer, academic exchange between doctors, remote consultation, patient referral, healthcare management model exchange, and technological innovation & application. In terms of talent training, Shanghai Artemed Hospital has established a two-way talent training model to build an international medical training center.
Shanghai Artemed Hospital is mainly aimed at being a research hospital. Relying on the extensive layout of biopharmaceutical manufacturing facilities of Hillhouse Capital, the Hospital will make every effort to build a clinical research platform and industrial transformation platform for oncology. It will bring together domestic and overseas first-class research institutions and clinical experts to build a collaborative research network and organize large-scale, multi-center, high-quality clinical research projects. It will take advantage of the policies in the Free Trade Zone to pioneer the realization of translational medicine integrated by new technologies, new products and clinical practice.
